Nektar Faces Fraud Lawsuit Over Failed Clinical Trial

Edgen Stock·Mar 16 2026, 16:22

Share to

Share to

Copy link

Key Takeaways

Multiple law firms are soliciting Nektar Therapeutics (NKTR) shareholders for a class-action lawsuit alleging securities fraud. The suit claims the company misled investors about the integrity of its REZOLVE-AA clinical trial between February and December 2025. The eventual failure of the trial caused a significant stock decline, prompting legal action.

Several law firms are investigating Nektar for allegedly making false and misleading statements to investors.
The lawsuit focuses on the company's failure to disclose protocol violations in its REZOLVE-AA clinical trial.
On December 16, 2025, news of the trial's failure caused Nektar's stock to fall 7.77% to $49.16.

Lawsuit Alleges Misleading Statements During 2025 Class Period

Nektar Therapeutics (NASDAQ: NKTR) is facing a securities fraud class-action lawsuit, with multiple law firms, including the Law Offices of Frank R. Cruz and Rosen Law Firm, encouraging shareholders to join. The lawsuit covers investors who purchased securities between February 26, 2025, and December 15, 2025. The core allegation is that Nektar made false and misleading statements about its clinical trial, REZOLVE-AA.

According to the complaint, Nektar failed to disclose that enrollment in the trial did not adhere to proper instructions and protocol standards. The suit claims that the company overstated the trial's integrity and prospects, thereby misleading the market about its potential for success. The deadline for an investor to move the Court to serve as lead plaintiff is May 5, 2026.

Trial Failure Triggers 7.77% Stock Plunge on December 16

The legal actions follow Nektar's announcement on December 16, 2025, that its Phase 2b REZOLVE-AA trial for investigational rezpegaldesleukin failed to reach statistical significance. The company attributed the failure to the improper inclusion of four patients who should not have been eligible to participate in the study.

This negative news directly impacted the company's valuation. On the day of the announcement, Nektar's stock price fell sharply by $4.14 per share, or 7.77%, to close at $49.16. The lawsuit claims that when these true details about the trial's integrity and outcome entered the market, investors who had purchased shares during the class period suffered damages.